Metabolomics of colistin methanesulfonate treated Mycobacterium tuberculosis

Over the last 5 years, there has been a renewed interest in finding new compounds with anti-TB action. Colistin methanesulfonate or polymyxin E, is a possible anti-TB drug candidate, which may in future be used either alone or in combination to the current 6 month “directly observed treatment short-course” (DOTS) regimen. However its mechanism of action has to date not yet been fully explored, and only described from a histological and genomics perspective. Considering this, we used a GCxGC-TOFMS metabolomics approach and identified those metabolite marke rs characterising Mycobacterium tuberculosis (Mtb) cultured in the presence of colistin methanesulfonate, in order to better understand or confirm its mechanism of action.

Source: Tuberculosis - June 13, 2018 Category: Respiratory Medicine Authors: Nadia Koen, Shane Vontelin van Breda, Du Toit Loots Source Type: research